Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): A randomised, placebo-controlled trial

The Lancet Neurology

Volumn 12, Issue 9, 2013, Pages 857-865

  Zajicek, John ^a   Ball, Susan ^a   Wright, David ^a   Vickery, Jane ^a   Nunn, Andrew ^b   Miller, David ^c   Cano, Mayam Gomez ^a   McManus, David ^c   Mallik, Sharukh ^c   Hobart, Jeremy ^a  

^a PLYMOUTH UNIVERSITY PENINSULA SCHOOLS OF MEDICINE AND DENTISTRY   (United Kingdom)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DRONABINOL; PLACEBO;

ADULT; AGED; ARTHROPATHY; ARTICLE; BALANCE DISORDER; CONSTIPATION; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DISEASE COURSE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; EXPANDED DISABILITY STATUS SCALE; FATIGUE; FECES INCONTINENCE; FEMALE; FOLLOW UP; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS IMPACT SCALE; MUSCLE RIGIDITY; MUSCLE SPASM; MUSCLE WEAKNESS; MYALGIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REHABILITATION CENTER; SPASTICITY; TREATMENT DURATION; TREMOR; URINARY TRACT INFECTION;

EID: 84881556664     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(13)70159-5     Document Type: Article

References (20)

1. Zajicek J, Fox P, Sanders H, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 2003, 362:1517-1526. on behalf of the UK MS Research Group.
2. Hampson AJ, Grimaldi M, Axelrod J, Wink D Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci USA 1998, 95:8268-8273.
3. Molina-Holgado E, Vela JM, Arevalo-Martin A, et al. Cannabinoids promote oligodendrocyte progenitor survival: involvement of cannabinoid receptors and phosphatidylinositol-3 kinase/Akt signaling. J Neurosci 2002, 22:9742-9753.
4. Skaper SD, Buriani A, Dal Toso R, et al. The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. Proc Natl Acad Sci USA 1996, 93:3984-3989.
5. Chang YH, Lee ST, Lin WW Effects of cannabinoids on LPS stimulated inflammatory mediator release from macrophages: involvement of eicosanoids. J Cell Biochem 2001, 81:715-723.
6. Arevalo-Martin A, Vela JM, Molina-Holgado E, et al. Therapeutic action of cannabinoids on a murine model of multiple sclerosis. J Neurosci 2003, 23:2511-2516.
7. Zajicek J, Fox P, Teare L, et al. Cannabinoids in multiple sclerosis (CAMS) study, safety and efficacy data from up to 12-months follow-up. J Neurol Neurosurg Psychiatry 2005, 76:1664-1669.
8. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001, 50:121-127.
9. Smith SM, De Stefano N, Jenkinson M, Matthews PM Normalised accurate measurement of longitudinal brain change. J Comput Assist Tomogr 2001, 25:466-475.
10. Smith SM, Zhang Y, Jenkinson M, et al. Accurate, robust and automated longitudinal and cross sectional brain change analysis. Neuroimage 2002, 17:479-489.
11. Randomised controlled trial of interferon-beta-1a in secondary progressive MS: clinical results. Neurology 2001, 56:1496-1504. SPECTRIMS Study Group.
12. R: a language and environment for statistical computing 2011, R development Core Team, R Foundation for Statistical Computing, Vienna, Austria.
13. Hobart J, Cano S Improving the evaluation of therapeutic interventions in multiple sclerosis: the role of new psychometric methods. Health Technol Assess 2009, 13:1-177.
14. Fischer JS, Jak AJ, Kniker JE, Rudick RA, Cutter GR Multiple sclerosis functional composite (MSFC) administration and scoring manual 2001, National Multiple Sclerosis Society, New York, NY.
15. Cohen JA, Cutter GR, Fischer JS, et al. Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial. Arch Neurol 2001, 58:961-967.
16. Molt RW, McAuley E, Mullen S Longitudinal measurement invariance of the multiple sclerosis walking scale-12. J Neurol Sci 2011, 305:75-79.
17. Pinheiro JC, Bates DM Mixed-effects models in S and S-PLUS 2000, Springer Verlag, New York.
18. Wolinsky JS, Narayana PA, O'Connor P, et al. Glatiramer acetate in primary progressive multiple sclerosis: results from a multinational multicenter double blind placebo controlled trial. Ann Neurol 2007, 61:14-24.
19. Novotna A, Mares J, Ratcliffe S, et al. A randomized double blind placebo-controlled, parallel group, enriched design study of nabiximols (Sativex) as add-on therapy in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol 2011, 18:1122-1131.
20. Zajicek J, Hobart J, Slade A, et al. Multiple sclerosis and extract of cannabis: results from the MUSEC trial. J Neurol Neurosurg Psychiatry 2012, 83:1125-1132.